AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.
Phase 1
Completed
- Conditions
- Healthy Volunteers Bioavailability Study
- Interventions
- Other: [14C] selumetinib IV solution
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT02238782
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)
Completed
- Conditions
- Dyslipidaemia
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2700
- Registration Number
- NCT02230241
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2018-12-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 695
- Registration Number
- NCT02229396
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 464
- Registration Number
- NCT02229383
- Locations
- 🇿🇦
Research Site, Worcester, South Africa
Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-08-29
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT02228369
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
Phase 2
Terminated
- Conditions
- Peripheral Artery Disease (PAD)
- Interventions
- Drug: Comparator
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT02227368
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Phase 3
Completed
- Conditions
- Homozygous Familial Hypercholesterolemia (HoFH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT02226198
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2014-08-27
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1869
- Registration Number
- NCT02226822
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol 'as needed' + budesonide placebo bidDrug: budesonode bid + terbutaline 'as needed'
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4215
- Registration Number
- NCT02224157
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Procedure: Pharmacokinetic sampling - AZD9291Drug: AZD9291 tablet dosingProcedure: Pharmacokinetic sampling - AZ5140 and AZ7550
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 136
- Registration Number
- NCT02224053
- Locations
- 🇺🇸
Research Site, Minneapolis, Minnesota, United States